Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those evaluating psilocybin for...
Introduction Research on psychedelic compounds has grown quickly in the past decade. Yet molecule-specific, quantitative summaries are scattered, making it hard to see how interest differs by compound or over time. Objectives To quantify PubMed-indexed publications on ketamine, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin, and psilocin; to describe annual trends...
A systematic review and meta‐analysis comprising 24 trials has concluded that when both psychedelic and antidepressant trials in the treatment of depression are unblinded, psychedelics are no more effective than open‐label antidepressants. The findings call into question some optimistic projections about the efficacy of psychedelics in depression treatment.
Recent studies show that psychedelics such as psilocybin and LSD can reliably occasion spiritual or “mystical-like” experiences under supportive conditions, and the spiritual dimension of these experiences may contribute to their reported mental health benefits. Scholars have begun exploring how such experiences might relate to spiritual growth within Christian frameworks, but most theological...
Background: Treatment-resistant depression (TRD) affects a significant proportion of individuals with major depressive disorder and remains difficult to manage with conventional treatments. Psychedelic-assisted therapies and neuromodulation have emerged as innovative interventions targeting neurobiological mechanisms beyond traditional antidepressant approaches. Objectives: This scoping review...
Psychedelic-assisted therapy (PAT) has demonstrated substantial efficacy across a range of mental disorders. However, heterogeneity between patients confers differential responsiveness. This systematic review aims to explore factors which may predict therapeutic responses to PAT. A systematic search was performed from inception through to March 2024 and studies that assessed predictors of...
Psychedelic drugs are increasingly under investigation as potential therapeutic agents for mental health conditions and are being increasingly used recreationally. Psychedelic use may result in an episode of intense psychological distress, commonly referred to as a "bad trip." Bad trips represent a potentially volatile, erratic, and dangerous situation, which may, in extreme cases, require...
Previous research suggests that psychedelics may, under certain conditions, decrease authoritarian attitudes, but larger and more rigorously designed studies are needed to confirm these findings. We aimed to examine the effects of psychedelic use on authoritarian attitudes. Using data from three separate studies with different designs and populations, we investigated the relationship between...
While psychedelics have shown initial promise in the treatment of migraine, experimental studies have relied on small and homogenous samples, which limit the reliability and generalizability of findings. These limitations underscore the complementary value of other research designs that leverage larger and more representative samples. This cross-sectional study included three cohorts of twins...
RATIONALE: Reports of resurfaced repressed memories during psychedelic experiences have circulated for decades and still emerge today. However, the veracity of repressed memories remains debated, and the mechanisms through which psychedelics might recover alleged repressed memories are unclear. OBJECTIVES: This scoping review aimed to provide an overview of the literature on repressed memory in...